Selective Agonists and Antagonists for 5-hydroxytryptamine Receptor Subtypes, and Interactions with Yohimbine and FG 7142 Using the Elevated Plus-maze Test in the Rat
Overview
Pharmacy
Authors
Affiliations
The effects of some 5-HT receptor ligands were investigated on measures of anxiety in an elevated plus-maze test in the rat. Quipazine (2 and 4 mg kg-1), a non-specific 5-HT agonist and ritanserin (0.25-10 mg kg-1), a 5-HT2 receptor antagonist displayed anxiogenic profiles by reducing both of the measures of anxiety used in this test. Two 5-HT1A receptor ligands, buspirone (4 and 8 mg kg-1) and ipsapirone (2.5-10 mg kg-1) and the 5-HT1 agonist, RU 24969 (0.1875-1.5 mg kg-1) significantly reduced only the percentage of time spent on the open arms. (-)-Propranolol (5 and 10 mg kg-1), a 5-HT1 receptor antagonist significantly reduced only the percentage of entries made onto the open arms. Metergoline (4 mg kg-1), a non-specific 5-HT antagonist displayed anxiolytic effects in this test by increasing both measures of anxiety. The 5-HT1A receptor agonist, 8-OH-DPAT (0.0625-0.25 mg kg-1) had no effect on either of the measures of anxiety. The results from the non-specific ligands (quipazine and metergoline) are consistent with the theory that a reduction in 5-HT function reduces anxiety. However, in spite of their more selective effects on 5-HT receptors the results in this test from the more specific ligands are not consistent with a strong involvement of any single receptor subtype. The interaction studies with yohimbine and FG 7142 (beta-carboline-3-carboxylate methylamide) provided no clear evidence for a major role of 5-HT pathways in the mediation of their anxiogenic effects.
Bortolasci C, Jaehne E, Hernandez D, Spolding B, Connor T, Panizzutti B Neurotox Res. 2023; 41(6):502-513.
PMID: 37922109 PMC: 10682262. DOI: 10.1007/s12640-023-00673-0.
McNaughton N Front Behav Neurosci. 2022; 16:877633.
PMID: 35619597 PMC: 9128611. DOI: 10.3389/fnbeh.2022.877633.
Greenwald M Neurobiol Stress. 2018; 9:84-104.
PMID: 30238023 PMC: 6138948. DOI: 10.1016/j.ynstr.2018.08.003.
Leon L, Castro-Gomes V, Zarate-Guerrero S, Corredor K, Mello Cruz A, Brandao M Front Behav Neurosci. 2017; 11:117.
PMID: 28736518 PMC: 5500641. DOI: 10.3389/fnbeh.2017.00117.
Walker L, Kastman H, Krstew E, Gundlach A, Lawrence A Br J Pharmacol. 2017; 174(19):3359-3369.
PMID: 28726252 PMC: 5595761. DOI: 10.1111/bph.13955.